Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire

31 Mar

REDWOOD CITY, Calif. & BOSTON, March 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

Details of the event are as follows:
Panel: "CAR T Approaches in the Autoimmune Space"
Date: Monday, April 7, 2025
Time: 3:00 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/

Contacts

Adicet Bio, Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly
kbdaly@adicetbio.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523910696"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523910696\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2523910696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 19:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2523910696","market":"us","top_or_hot":-1,"title":"Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"288\" src=\"https://s.yimg.com/uu/api/res/1.2/6jILxMZ1RfTCftJ.J9Y79A--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/2834b44c822e0775682db9203fb8d2ce\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>REDWOOD CITY, Calif. &amp; BOSTON, March 31, 2025</b>--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.</p>\n<p>Details of the event are as follows:<br/>Panel: \"CAR T Approaches in the Autoimmune Space\"<br/>Date: Monday, April 7, 2025<br/>Time: 3:00 p.m. ET<br/><br/><br/></p>\n<p><b>About Adicet Bio, Inc.</b></p>\n<p>Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of \"off-the-shelf\" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250331839401/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Adicet Bio, Inc. </b><br/><b>Investor and Media Contacts</b><br/></p>\n<p><b>Investors: </b><br/>Anne Bowdidge<br/>abowdidge@adicetbio.com<br/><br/></p>\n<p>Janhavi Mohite<br/>Precision AQ<br/>212-362-1200<br/>janhavi.mohite@precisionaq.com<br/><br/><br/></p>\n<p><b>Media: </b><br/>Kerry Beth Daly<br/>kbdaly@adicetbio.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-31 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/adicet-bio-participate-2025-canaccord-110000670.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>REDWOOD CITY, Calif. & BOSTON, March 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...</p>\n\n<a href=\"https://finance.yahoo.com/news/adicet-bio-participate-2025-canaccord-110000670.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACET","symbol_name":"艾切托","start_time":0,"source_url":"https://finance.yahoo.com/news/adicet-bio-participate-2025-canaccord-110000670.html","article_id":"2523910696","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523910696","pubTimestamp":1743418800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"REDWOOD CITY, Calif. & BOSTON, March 31, 2025----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.Details of the event are as follows:Panel: \"CAR T Approaches in the Autoimmune Space\"Date: Monday, April 7, 2025Time: 3:00 p.m. ET","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACET":"艾切托","BK4139":"生物科技"},"translate_title":"Adicet Bio将参加2025年Canaccord Genuity Horizons in Oncology虚拟会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACET":0.9},"content_text":"REDWOOD CITY, Calif. & BOSTON, March 31, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.\nDetails of the event are as follows:Panel: \"CAR T Approaches in the Autoimmune Space\"Date: Monday, April 7, 2025Time: 3:00 p.m. ET\nAbout Adicet Bio, Inc.\nAdicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of \"off-the-shelf\" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250331839401/en/\nContacts\nAdicet Bio, Inc. Investor and Media Contacts\nInvestors: Anne Bowdidgeabowdidge@adicetbio.com\nJanhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com\nMedia: Kerry Beth Dalykbdaly@adicetbio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}